MBX Stock Analysis: Buy, Sell, or Hold?
MBX - MBX Biosciences, Inc. Common Stock
$27.26
-1.24 (-4.35%)
▼
5d:
-3.13%
30d:
-16.25%
90d:
-11.78%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 11, 2026
Get Alerted When MBX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: MBX shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: MBX shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: MBX is currently trading at $27.26, which is considered oversold relative to its 30-day fair value range of $27.68 to $33.88.
Technical Outlook: Technically, MBX is in a uptrend. The price is currently testing key support at $26.84. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $61.30 (+115.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MBX is in a uptrend. The price is currently testing key support at $26.84. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $61.30 (+115.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$27.68 -
$33.88
Company Quality Score
52/100
(HOLD)
Options IV Signal
50th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
75.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 50th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.4%)
- BULLISH: Trading 115.1% below Wall St target ($61.30)
Fair Price Analysis
30-Day Fair Range
$27.68 -
$33.88
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$3.52
(12.9%)
Support & Resistance Levels
Support Level
$26.84
Resistance Level
$31.20
Current Trend
Uptrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.72
Wall Street Target
$61.30
(+115.1%)
Share & Embed Analysis
Last updated: March 30, 2026 10:24 AM ET
Data refreshes hourly during market hours. Next update: 11:24 AM
Data refreshes hourly during market hours. Next update: 11:24 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MBX showing a specific setup today?
Insider Activity (6 Months)
3
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
P. Kent Hawryluk
BUY
18500 shares
2026-03-13
P. Kent Hawryluk
BUY
20000 shares
2025-10-20
Steven L Hoerter
BUY
20000 shares
2025-10-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 47 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 61 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 49 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$109 | 51 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 58 HOLD |
